Group by Gene: Chemotherapy DNA BCL Inhibitors EGFR Tyrosine Kinase Inhibitors CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy | PD1 inhibitor pembrolizumab | nivolumab | Thymidylate synthase inhibitor 5-fluorouracil | capecitabine | EGFR inhibitor cetuximab | Tubulin polymerization promoter, Bcl2 inhibitor carboplatin + paclitaxel | paclitaxel | THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor methotrexate | Tubulin polymerization promoter carboplatin | DNA synthesis inhibitor cisplatin | PD1 inhibitor, EGFR inhibitor pembrolizumab + cetuximab | Microtubule stabilizer, Tubulin polymerization promoter docetaxel | HER2 inhibitor, HER4 inhibitor, EGFR inhibitor afatinib | Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor, Thymidylate synthase inhibitor cisplatin + paclitaxel + 5-fluorouracil | DNA synthesis inhibitor, Thymidylate synthase inhibitor cisplatin + 5-fluorouracil | DNA synthesis inhibitor, Thymidylate synthase inhibitor, Ribonucleotide reductase inhibitor 5-fluorouracil + hydroxyurea | Tubulin polymerization promoter, Thymidylate synthase inhibitor carboplatin + 5-fluorouracil | Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor cisplatin + paclitaxel | Chemotherapy TPF | Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor cisplatin + docetaxel |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No biomarker | ||||||||||||||||||||
PD-L1 expression | ||||||||||||||||||||
ITGAE overexpression |